Covalent drugs have been used to treat diseases for more than a century, but tools that
facilitate the rational design of covalent drugs have emerged more recently. The purposeful …

Covalent inhibitors and other types of covalent modalities have seen a revival in the past two
decades, with a variety of new targeted covalent drugs having been approved in recent …

Recent advances in chemical proteomics have begun to characterize the reactivity and
ligandability of lysines on a global scale. Yet, only a limited diversity of aminophilic …

Advances in chemoproteomic technology have revealed covalent interactions between
small molecules and protein nucleophiles, primarily cysteine, on a proteome-wide scale …

Post-translational modifications are an area of great interest in mass spectrometry-based
proteomics, with a surge in methods to detect them in recent years. However, post …

Cysteine chemoproteomics provides proteome-wide portraits of the ligandability or potential"
druggability" for thousands of cysteine residues. Consequently, these studies are facilitating …

K-Ras is the most commonly mutated oncogene in human cancer. The recently approved
non-small cell lung cancer drugs sotorasib and adagrasib covalently capture an acquired …

Peptide-based covalent probes can target shallow protein surfaces not typically addressable
using small molecules, yet there is a need for versatile approaches to convert native peptide …